(93 days)
No
The document describes image processing algorithms (Premium View, PVi, eContrast) that are rule-based and adjustable by the user, not AI/ML. There is no mention of training data, models, or adaptive learning.
No
The device is described as an image post-processing algorithm for digital mammography systems, which aids in the diagnosis and screening of breast cancer by improving image visibility. It does not directly provide therapy.
Yes
The "Intended Use / Indications for Use" section explicitly states that the images generated by the system "can be used for screening and in the diagnosis of breast cancer." While eContrast is a post-processing algorithm, it is part of a system intended for diagnosis.
Yes
The device description explicitly states, "The subject of this submission is a software-only option... eContrast is a Software only option."
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use clearly states that the system generates digital mammographic images for screening and diagnosis of breast cancer. It is used in the same clinical applications as traditional film-based mammographic systems. This describes an imaging system used for diagnostic purposes, not a test performed in vitro on biological specimens.
- Device Description: The device is described as a software-only option for a Full Field Digital Mammography (FFDM) system. This further reinforces that it's part of an imaging modality.
- Lack of IVD Characteristics: There is no mention of analyzing biological samples (blood, tissue, etc.), reagents, or any other components typically associated with in vitro diagnostic tests.
The device is a medical imaging system with advanced image processing capabilities to aid radiologists in interpreting mammograms.
N/A
Intended Use / Indications for Use
The Senographe DS and Senographe Essential FFDM systems generate digital mammographic images that can be used for screening and in the diagnosis of breast cancer. The Senographe DS and Senographe Essential FFDM systems are intended to be used in the same clinical applications as traditional film-based mammographic systems.
Premium View is an image-processing algorithm, which increases the visibility of breast structures. The main advantage is to provide a single breast image, where the contrast in the fatty tissues is similar to that obtained by setting WW (window width) and WL (window level) for optimum visualization of fatty tissues, and the contrast in the fibro-glandular tissue is similar to that obtained by setting WW and WL for optimal visualization of fibro-glandular tissues.
Premium View I (PVi) is an option that can simplify the presentation of mammographic images, improve workflow, and streamline the review process of images with very dark or bright areas by presenting the image with the WW and WL optimized for review with minimal need for the user to make adjustments for the various tissue areas. This could be especially useful with patients who have very thin breasts, very dense breasts, or implants that currently require multiple adjustments of WW and WL to review.
eContrast accommodates different customer display preferences in screening and diagnosis, with 5 different levels, while keeping the PVi option for implants. eContrast post-processing is also available for stereo images.
Product codes
MUE
Device Description
The subject of this submission is a software-only option to Senographe Essential Full Field Digital Mammography (FFDM) system called eContrast. eContrast is an image post-processing algorithm that will introduce a modification to the previously approved Premium View (PV) / Premium View i (PVi) (K110798). eContrast processing will offer 6 levels of contrast strength for image viewing, where the desired combination of image sharpness, image smoothness, level of tissue penetration, and level of contrast may be selected by the radiologist. The final image appearance varies according to the selected level. eContrast is a Software only option.
Mentions image processing
Yes
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Digital Mammography
Anatomical Site
Breast
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Radiologist
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
The subject of this premarket submission, eContrast option, included clinical testing to quantify the clinical acceptance of images that had been retrospectively processed with this image processing algorithm.
The subject of this premarket submission, eContrast image processing option, included clinical image evaluation to quantify the clinical acceptance of images that had been retrospectively processed with this image processing algorithm.
The objective of the eContrast clinical evaluation was to determine if the images retrospectively processed with the new processing still provided acceptable clinical image quality.
The evaluation was based on BIRADS 1 or 2 patients with two fatty breasts, two dense breasts, and 2 images that were in between. This was done to show that the image processing would be acceptable across all types of patients as suggested in the Class II Special Controls Guidance Document for FFDM systems.
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Clinical evaluation to quantify the clinical acceptance of images retrospectively processed with the image processing algorithm. The evaluation was based on BIRADS 1 or 2 patients with two fatty breasts, two dense breasts, and 2 images that were in between. The study aimed to show that the image processing would be acceptable across all types of patients.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Senographe Essential-P990066/S21 with Premium View i K110798
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 892.1715 Full-field digital mammography system.
(a)
Identification. A full-field digital mammography system is a device intended to produce planar digital x-ray images of the entire breast. This generic type of device may include digital mammography acquisition software, full-field digital image receptor, acquisition workstation, automatic exposure control, image processing and reconstruction programs, patient and equipment supports, component parts, and accessories.(b)
Classification. Class II (special controls). The special control for the device is FDA's guidance document entitled “Class II Special Controls Guidance Document: Full-Field Digital Mammography System.”See § 892.1(e) for the availability of this guidance document.
0
Image /page/0/Picture/0 description: The image shows a document with handwritten text. The text at the top reads "K131885 Page 1 of 4". In the lower left corner, there is a logo that appears to be the GE logo. The document seems to be the first page of a four-page document.
GE Healthcare
510(k) Premarket Notification Submission
510(k) Summary
In accordance with 21 CFR 807.92 the following summary of information is provided:
| Date: | 20 June 2013 |
|---|---|
| Submitter: | GE Healthcare |
| GE Medical Systems SCS | |
| 283 RUE DE LA MINIERE | |
| 78530 BUC - FRANCE | |
| Primary Contact Person: | Mounir Zaouali, RAC |
| Regulatory Affairs Leader | |
| GE Healthcare, (GE Medical Systems, SCS) | |
| 283 RUE DE LA MINIERE | |
| 78530 BUC - FRANCE | |
| Phone : + 33 1 30 70 45 39 | |
| Fax : + 33 1 30 70 41 40 | |
| Mounir.Zaouali@ge.com | |
| Secondary Contact Person: | Steven Kachelmeyer, RAC |
| Regulatory Affairs Director - X-ray | |
| GE Healthcare | |
| Phone: 262-548-2432 | |
| Fax: 262-997-1080 | |
| Steven.Kachelmeyer@med.ge.com | |
| Device Trade Name: | eContrast |
| Common/Usual Name: | Full Field Digital Mammography System |
| Classification Names: | |
| Product Code: | 21 CFR 892.1715, Class II |
| MUE | |
| Predicate Device(s): | Senographe Essential-P990066/S21 with Premium View i |
| K110798 | |
| Device Description: | The subject of this submission is a software-only option to |
| Senographe Essential Full Field Digital Mammography (FFDM) | |
| system called eContrast. | |
| eContrast is an image post-processing algorithm that will | |
| introduce a modification to the previously approved Premium | |
| View (PV) / Premium View i (PVi) (K110798). eContrast | |
| processing will offer 6 levels of contrast strength for image | |
| viewing, where the desired combination of image sharpness, | |
| image smoothness, level of tissue penetration, and level of | |
| contrast may be selected by the radiologist. The final image | |
| appearance varies according to the selected level. | |
| eContrast is a Software only option. | |
| Intended Use: | The Senographe DS and Senographe Essential FFDM systems |
| generate digital mammographic images that can be used for | |
| screening and in the diagnosis of breast cancer. The | |
| Senographe DS and Senographe Essential FFDM systems are | |
| intended to be used in the same clinical applications as | |
| traditional film-based mammographic systems. | |
| Premium View is an image-processing algorithm, which | |
| increases the visibility of breast structures. The main advantage | |
| is to provide a single breast image, where the contrast in the | |
| fatty tissues is similar to that obtained by setting WW (window | |
| width) and WL (window level) for optimum visualization of fatty | |
| tissues, and the contrast in the fibro-glandular tissue is similar | |
| to that obtained by setting WW and WL for optimal visualization | |
| of fibro-glandular tissues. | |
| Premium View I (PVi) is an option that can simplify the | |
| presentation of mammographic images, improve workflow, and | |
| streamline the review process of images with very dark or | |
| bright areas by presenting the image with the WW and WL | |
| optimized for review with minimal need for the user to make | |
| adjustments for the various tissue areas. This could be | |
| especially useful with patients who have very thin breasts, very | |
| dense breasts, or implants that currently require multiple | |
| adjustments of WW and WL to review. | |
| eContrast accommodates different customer display | |
| preferences in screening and diagnosis, with 5 different levels, | |
| while keeping the PVi option for implants. eContrast post- | |
| processing is also available for stereo images. | |
| Technology: | The eContrast processing is an image post-processing that |
| provides an image display for all breast tissue (fatty and | |
| fibroglandular) from the chest to the nipple in a single image. | |
| After acquisition, eContrast is applied to the image to create the | |
| processed image which then replaces the raw image on the | |
| screen of the acquisition workstation. | |
| The main calculations that are applied to create the processed | |
| image are: | |
| • Collimator Detection: | |
| This applies a black mask around the useful image area, | |
| covering areas which would otherwise be white. It allows more | |
| comfortable viewing. | |
| • Pseudo-log Transformation: | |
| This transformation facilitates the manipulation of brightness | |
| and contrast during the review. After the transformation, the | |
| image dynamic range is reduced to 12 bits, without loss of | |
| clinical information. | |
| • Thickness Equalization: | |
| This equalizes the grey level range all over the breast including | |
| the tissue not under compression and close to the skin line. | |
| • Dynamic Range Management: | |
| This computation locally increases contrast and sharpness for | |
| structure of interest. This effect can be reinforced based on user | |
| preferences. | |
| • Auto-contrast: | |
| This improves image quality by optimizing brightness levels | |
| (window level) and contrast (window width) in the image. | |
| Determination of | |
| Substantial Equivalence: | Summary of Non-Clinical Tests: |
| The eContrast option complies with voluntary standards. The | |
| following quality assurance measures were applied to the | |
| development of the system: | |
| • Risk Analysis | |
| • Requirements Reviews | |
| • Design Reviews | |
| • Testing on unit level (Module verification) | |
| • Integration testing (System verification) | |
| • Performance testing (Verification) | |
| • Safety testing (Verification) | |
| • Simulated use testing (Validation) | |
| Summary of Clinical Tests: | |
| The subject of this premarket submission, eContrast option, included clinical testing to quantify the clinical acceptance of images that had been retrospectively processed with this image processing algorithm. | |
| The subject of this premarket submission, eContrast image processing option, included clinical image evaluation to quantify the clinical acceptance of images that had been retrospectively processed with this image processing algorithm. | |
| The objective of the eContrast clinical evaluation was to determine if the images retrospectively processed with the new processing still provided acceptable clinical image quality. | |
| The evaluation was based on BIRADS 1 or 2 patients with two fatty breasts, two dense breasts, and 2 images that were in between. This was done to show that the image processing would be acceptable across all types of patients as suggested in the Class II Special Controls Guidance Document for FFDM systems. | |
| Conclusion: | GE Healthcare considers the eContrast option to be as safe, as effective, and performance is substantially equivalent to the predicate device. |
·
1
Image /page/1/Picture/0 description: The image shows the General Electric (GE) logo. The logo consists of the letters "GE" written in a stylized script, enclosed within a circular border. The background within the circle is black, while the letters and the border are white. The logo is a well-known symbol associated with the General Electric company.
GE Healthcare
510(k) Premarket Notification Submission
.
2
GE Healthcare
510(k) Premarket Notification Submission
Image /page/2/Picture/2 description: The image shows the General Electric (GE) logo. The logo consists of the letters "GE" in a stylized font, enclosed within a circular frame. The letters and the frame are black, contrasting with the white background. The logo is a well-known symbol associated with the General Electric company.
.
:
:
:
3
K131885
Page 4 of 4
ר
GE Healthcare
510(k) Premarket Notification Submission
4
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/4/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized caduceus symbol, which is a staff with two snakes entwined around it, and the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged in a circular fashion around the symbol. The logo is black and white.
Public Health Service
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
September 26, 2013
GE Heathcare % Mr. Mounir Zaouali Regulatory Affairs Leader 283 Rue de la Minière Buc. 78530 FRANCE
Re: K131885
Trade/Device Name: eContrast Regulation Number: 21 CFR 892.1715 Regulation Name: Digital Full Field Mammography Regulatory Class: Class II Product Code: MUE Dated: August 26, 2013 Received: August 28, 2013
Dear Mr. Zaouali:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (2 l CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set
5
Page 2 - Mr. Zaouali
forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Small Manufacturers, International and Consumer Assistance at its tollfree number (800) 638 2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industrv/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21) CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safetv/ReportaProblem/delault.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours,
for
Janine M. Morris Director, Division of Radiological Health Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health
Enclosure
6
Indications for Use
510(k) Number (if known): K131885
Device Name: eContrast
Indications for Use:
The Senographe Essential FFDM systems generate digital mammographic images that can be used for screening and in the diagnosis of breast cancer. The Senographe Essential FFDM systems are intended to be used in the same clinical applications as traditional film-based mammographic systems.
Premium View is an image-processing algorithm, which increases the visibility of breast structures. The main advantage is to provide a single breast image, where the contrast in the fatty tissues is similar to that obtained by setting WW (window width) and WL (window level) for optimum visualization of fatty tissues, and the contrast in the fibro-glandular tissue is similar to that obtained by setting WW and WL for optimal visualization of fibro-glandular tissues.
PVi is an option that can simplify the presentation of mammographic images, improve workflow, and streamline the review process of images with very dark or bright areas by presenting the image with the WW and WL optimized for review with minimal need for the user to make adjustments for the various tissue areas. This could be especially useful with patients who have very thin breasts, very dense breasts, or implants that currently require multiple adjustments of WW and WL to review.
eContrast accommodates different customer display preferences in screening and diagnosis, with 5 different levels, while keeping the PV i option for implants. eContrast postprocessing is also available for stereo images.
Prescription Use X =========================================================================================================================================================== (Part 21 CFR 801 Subpart D) AND/OR
Over-The-Counter Use (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of In Vitro Diagnostics and Radiological Health (OIR)
$m_{h,3}$
(Division Sign-Off) Division of Radiological Health Office of In Vitro Diagnostics and Radiological Health
210(k) K131882
Page 1 of 1